GlassScriptPhysician profile
Jeffrey Schneider
NPI 1700032711
$9,284.59
in general payments reported to CMS, 2019-2025
52 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,658 · 2020: $1,095 · 2021: $298 · 2022: $711 · 2023: $1,461 · 2024: $1,889 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,522.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,850.22 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Abbott Laboratories | $849.78 | 2019-2025 | Proclaim, Eterna, Octrode |
| Pfizer INC. | $837.23 | 2019-2025 | |
| Lundbeck LLC | $527.55 | 2023-2025 | Vyepti |
| Averitas Pharma INC. | $416.67 | 2023-2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $394.13 | 2019-2025 | Xtampza, Belbuca |
| Pacira Therapeutics, INC. | $334.61 | 2019-2020 | |
| Vertos Medical, INC. | $288.41 | 2019-2024 | Mild Device Kit |
| Nalu Medical, INC. | $282.11 | 2021-2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $223.50 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $221.54 | 2019-2024 | Senza |
| Ferring Pharmaceuticals INC. | $186.47 | 2019-2020 | |
| Allergan, INC. | $186.10 | 2020 | |
| Scilex Pharmaceuticals INC. | $185.95 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $164.17 | 2019-2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.